TY - JOUR
T1 - New directions in cellular therapy of cancer
T2 - A summary of the summit on cellular therapy for cancer
AU - Stroncek, David F.
AU - Berger, Carolina
AU - Cheever, Martin A.
AU - Childs, Richard W.
AU - Dudley, Mark E.
AU - Flynn, Peter
AU - Gattinoni, Luca
AU - Heath, James R.
AU - Kalos, Michael
AU - Marincola, Francesco M.
AU - Miller, Jeffrey S.
AU - Mostoslavsky, Gustavo
AU - Powell, Daniel J.
AU - Rao, Mahendra
AU - Restifo, Nicholas P.
AU - Rosenberg, Steven A.
AU - O'Shea, John
AU - Melief, Cornelis J.M.
PY - 2012/3/15
Y1 - 2012/3/15
N2 - A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.
AB - A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies.
UR - http://www.scopus.com/inward/record.url?scp=84862805383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862805383&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-10-48
DO - 10.1186/1479-5876-10-48
M3 - Article
C2 - 22420641
AN - SCOPUS:84862805383
SN - 1479-5876
VL - 10
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 48
ER -
